Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 7:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 770 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hb-SS Disease Clear all
Completed No phase listed Observational Results available

Comparison of Patient Centered Outcomes for People With Sickle Cell Disease in the Acute Care Setting

NCT02411396
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Baton Rouge, Louisiana • Cleveland, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 22, 2026, 7:23 AM EDT
Withdrawn Phase 2 Interventional

Dipyridamole/Magnesium To Improve Sickle Cell Hydration

NCT00276146
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
oral dipyridamole, oral magnesium, or a combination of both
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years and older
Timeline
Started 2005
U.S. locations
3
States / cities
Detroit, Michigan • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 22, 2026, 7:23 AM EDT
Recruiting Phase 2 Interventional

Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults

NCT07369024
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease, Ketamine Infusion, Pain Management, Vaso-Occlusive Crises
Interventions
Sub-dissociative Ketamine Infusion, Normal Saline Placebo Infusion
Drug
Lead sponsor
Mohsen Saidinejad
Other
Eligibility
5 Years to 20 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 22, 2026, 7:23 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease

NCT01000155
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia
Interventions
vorinostat
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 22, 2026, 7:23 AM EDT
Recruiting Phase 1 Interventional

131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)

NCT07015684
View directory record Official record
Conditions
Sickling Disorder Due to Hemoglobin S
Interventions
131I-apamistmab, Sirolimus, Campath, Total Body Irradiation, Exchange Transfusion, Planar gamma imaging
Drug · Radiation · Procedure
Lead sponsor
Columbia University
Other
Eligibility
12 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 22, 2026, 7:23 AM EDT
Completed Not applicable Interventional Results available

Music Therapy in Sickle Cell Transition Study

NCT02466555
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Music Therapy
Behavioral
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 23 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 13, 2019 · Synced Oct 22, 2026, 7:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sickle Cell Pro-Inflammatory Response to Interval Training Study

NCT03653676
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Exercise Test (CIIT)
Other
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
10 Years to 21 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
3
States / cities
Chicago, Illinois • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 22, 2026, 7:23 AM EDT
Recruiting Not applicable Interventional

Advancing Feasibility and Acceptability of Digital Cognitive Rehabilitation in Sickle Cell Disease

NCT06770010
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Cogmed+
Behavioral
Lead sponsor
Children's National Research Institute
Other
Eligibility
7 Years to 16 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 22, 2026, 7:23 AM EDT
Completed Phase 2 Interventional

Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions

NCT00067080
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
ICL670, deferoxamine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
34
States / cities
Mobile, Alabama • Loma Linda, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 22, 2026, 7:23 AM EDT
Completed Not applicable Interventional Results available

Improving Self-Management in Adolescents With Sickle Cell Disease

NCT02851615
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
SCThrive Intervention for Adolescents with SCD
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
13 Years to 21 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 22, 2026, 7:23 AM EDT
Completed Not applicable Interventional

HRV-B for Symptom Management in Sickle Cell Patients

NCT03383913
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Heart Rate Variability Biofeedback
Behavioral
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
10 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Oct 22, 2026, 7:23 AM EDT
Completed Phase 2 Interventional Results available

Vitamin D for Sickle-cell Respiratory Complications

NCT01443728
View directory record Official record
Conditions
Sickle Cell Disease, Vitamin D Deficiency, Acute Chest Syndrome, Asthma, Respiratory Infections
Interventions
Experimental: Vitamin D3 100,000 IU, Active Comparator: Vitamin D3 12,000 IU
Drug
Lead sponsor
Gary M Brittenham, MD
Other
Eligibility
3 Years to 20 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 22, 2026, 7:23 AM EDT
Terminated Phase 2 Interventional Results available

A Study of IMR-687 in Subjects With Sickle Cell Disease

NCT04474314
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
IMR-687, Placebo
Drug
Lead sponsor
Cardurion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
14
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 22, 2026, 7:23 AM EDT
Completed Phase 4 Interventional Results available

Actigraphy Improvement With Voxelotor (ActIVe) Study

NCT04400487
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia
Interventions
Voxelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Farmington, Connecticut • Atlanta, Georgia • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Oct 22, 2026, 7:23 AM EDT
Withdrawn Phase 4 Interventional

Voxelotor Brain Oxygenation and Neurocognitive Study

NCT05228821
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Voxelotor Oral Tablet
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 30 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
2
States / cities
St Louis, Missouri • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 22, 2026, 7:23 AM EDT
Withdrawn Phase 1 Interventional

A Study of Oral L-citrulline in Sickle Cell Disease

NCT02659644
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Oral L-citrulline
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
10 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jun 21, 2018 · Synced Oct 22, 2026, 7:23 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Genotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and Adenosine Triphosphate Activities in Red Blood Cells of People With Sickle Cell Disease

NCT03685721
View directory record Official record
Conditions
Sickle Cell, PKLR Variants, Adenosine Triphosphate Activities
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 22, 2026, 7:23 AM EDT
Completed No phase listed Observational

Exploring Near Infrared Spectroscopy (NIRS) Technologies for Assessment of Muscle Physiology, Tissue Oxygenation, and Blood Flow in Patients With Sickle Cell Disease (SCD)

NCT05604547
View directory record Official record
Conditions
SCD
Interventions
Non-Invasive Infrared Spectroscopy
Diagnostic Test
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 22, 2026, 7:23 AM EDT
Completed Not applicable Interventional

Study of Clotrimazole and Hydroxyurea in Patients With Sickle Cell Syndromes

NCT00004404
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
clotrimazole, hydroxyurea
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 22, 2026, 7:23 AM EDT
Completed Phase 1 Interventional

Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease

NCT00095472
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
L-NMMA, Sodium Nitrite
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Oct 22, 2026, 7:23 AM EDT
Completed Not applicable Interventional

Home-based Assessment of PRO Measures in SCD Using A Smartphone App Platform: A Feasibility Study

NCT04678037
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Hemoglobin C, Sickle Beta Zero Thalassemia, Sickle B+ Thalassemia
Interventions
PROs assessment using sickle cell disease mobile app (SCD-app)
Behavioral
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
12 Years to 25 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 22, 2026, 7:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation

NCT03513328
View directory record Official record
Conditions
Bone Marrow Failure Syndrome, Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia, Acquired Neutropenia in Newborn, Acquired Anemia Hemolytic, Acquired Thrombocytopenia, Hemophagocytic Lymphohistiocytoses, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, Common Variable Immunodeficiency, X-linked Lymphoproliferative Disease, Severe Combined Immunodeficiency, Hurler Syndrome, Mannosidosis, Adrenoleukodystrophy
Interventions
Thiotepa--single daily dose, Thiotepa--escalated dose
Drug
Lead sponsor
University of Florida
Other
Eligibility
3 Months to 39 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 22, 2026, 7:23 AM EDT
Terminated Phase 2 Interventional Results available

Topical Sodium Nitrite in Sickle Cell Disease and Leg Ulcers

NCT02863068
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Topical Sodium Nitrite, Placebo
Drug · Other
Lead sponsor
caterina P minniti
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
The Bronx, New York • Durham, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Oct 22, 2026, 7:23 AM EDT
Terminated Phase 3 Interventional

A Stratified Sickle Event Randomized Trial (ASSERT)

NCT00102791
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
ICA-17043
Drug
Lead sponsor
Icagen
Industry
Eligibility
16 Years to 65 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
42
States / cities
Mobile, Alabama • Little Rock, Arkansas • Davis, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2008 · Synced Oct 22, 2026, 7:23 AM EDT